REBECCA SMITH: Open Payments
NPI 1720693740 · GLEN ALLEN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,196 in 63 payments from 11 companies in 2025. Trend: 2023 $901 · 2024 $947 · 2025 $1,196
Food & beverage: $1,196
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $233 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $203 |
| Vanda Pharmaceuticals Inc. | 7 | $191 |
| ABBVIE INC. | 12 | $173 |
| Alkermes, Inc. | 7 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Janssen Pharmaceuticals, Inc | 2 | $54 |
| Corium, LLC | 2 | $50 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $24 |
Products named: CAPLYTA, FANAPT, REXULTI, VRAYLAR, ARISTADA, TRINTELLIX, SPRAVATO, Azstarys.
Industry payments across VA — which companies pay providers there.
